Neoplasms

Nervous System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Prolactinoma

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pituitary Diseases

Pituitary Neoplasms

Endocrine Gland Neoplasms

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

All Drugs and Chemicals

Cardiotonic Agents

Hormones

Dopamine

Dopamine Agonists

Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.

Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.

The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .

Surgery

The medication will continue if DA causes tumors to shrink.

Drug treatment

Weiting Gu, MD

Zhebao Wu, Medical PhD

To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients. It had been showed that DA inhibit prolactin secretion by binding to and activating dopamine D2 receptors.PET-MR combined MR images with PET function images is substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of DA.

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.

The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.

Record the result of PRL on every 3 month follow-up visit

Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visits

Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind

Record the Visual acuity on every 3 month follow-up visit.

Xinqiao Hospital of Chongqing

First Hospital of China Medical University

Beijing Tiantan Hospital

First Affiliated Hospital of Wenzhou Medical University

First Affiliated Hospital of Fujian Medical University

Peking Union Medical College Hospital

Huashan Hospital

Chinese PLA General Hospital

Zhebao Wu

Principal Investigator

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Anti-Dyskinesia Agents

Cabergoline

Bromocriptine

Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.

Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.

Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.

Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .

To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.

Dopamine agonists are the first line therapy for prolactinoma,which are also effective in some cases of other subtypes of pituitary tumors. It had been showed that dopamine agonists inhibit prolactin secretion by binding to and activating dopamine D2 receptors. PET-MR combined MR images with PET function images is substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma

Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）.

Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visit.

2.Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

Hematinics

Amino Acids

Immune Checkpoint Inhibitors

Liver Extracts

Tyrosine Kinase Inhibitors

Tyrosine

Y-90 radioembolization therapy is the main treatment

Radiation therapy

Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors

Pierce Chow

This project is a pilot study to interrogate the potential of LMS as a predictive tool for the selection of therapy for HCC patients. The reliability of LMS to predict patients' response following HCC therapy will leverage on an algorithm that is built from the pool of MRI scans from HCC patients pre- and post-treatment. In the study, MRI scans of 30 HCC and metastatic colorectal cancer (CM) patients (ratio of 4:1) will be analysed. CM cancer patients include patients whose cancers metastasized from colorectal cancer or primary liver cancer. These patients will either receive one of the treatment, surgical resection, Y90 or systemic therapy. A total of 4 MRI scans will be taken for each patient; the first MRI scan will be taken within a month before treatment initiation and the remaining MRI scans will be taken at the 1st, 3rd and 9th month post-initiation of treatment.

Liver cancer is currently the second most common cause of cancer-related death worldwide, and hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers. There has been a marked increase in HCC-related annual death rates over the past two decades, with the majority of all cases of HCC worldwide found in the Asia-Pacific region. As such, HCC represents a major public health problem in the Asia-Pacific region and globally. There are a significant number of variables known to influence the prognosis of HCC, with the stage of underlying liver disease being a dominant factor. Elucidating these variables remains a challenge and the poor understanding of these variables has translated to poor prognostication of treatment outcomes. To date, no ideal predictive modality has been developed. One of the treatment therapies in HCC is surgical resection. Despite advances in the surgical and perioperative fields, potential posthepatectomy liver failure (PHLF) persists as a life-threatening complication, and is reported in up to 15% of patients (Aliza et al., 2017). This accentuates the need to develop accurate methods to quantitatively characterize future liver remnants (FLR) prior to surgery, as postoperative outcomes mainly depend on the size and quality of FLR (Cieslak et al., 2014).

This study seeks to address this unmet need as we will employ the LMS platform to assess and monitor changes in the liver health of HCC patients following treatment. In addition, this platform will be leveraged upon to monitor patients' response to the different treatment modalities such as surgical resection, Y90 and systemic therapy. These aims will be achieved through the quantitative characterization of liver tissues, which forms the basis of LMS technology. LMS is an MRI-based non-invasive tool that has attained CE marking and FDA clearance to aid the diagnosis of patients with liver disease. This technology is highly sensitive to subtle differences in liver tissue composition and samples the entire liver quickly, rendering it an ideal platform for liver tissue characterisation. LMS uses MRI mapping techniques to characterize liver tissue at the cellular level, delivering the quantification of liver fat and correlates of fibroinflammation and iron load using proton density fat fraction (PDFF), T1 and T2\* maps, respectively. The modelling algorithms of this device correct the T1 map (cT1) for the confounding effect of iron overload. In addition, this platform has further refined the measurements for PDFF to be more accurate in liver tissue characterisation. Previously, the use of LMS to predict clinical outcomes through tissue characterisation has been validated in a few clinical studies on patients with liver disease. In a prospective general hepatology clinical cohort following 112 patients for a median of 27 months, patients with higher cT1 values tended to experience clinical events, whereas patients with normal or low cT1 values had no clinical events (Pavlides et al., 2016). Additionally, from a prospective study on 71 patients with suspected non-alcoholic fatty liver disease (NAFLD), cT1 values have been shown to correlated with cirrhosis, ballooning and significant NAFLD (Pavlides et al., 2016). Finally, an independent study has also demonstrated the utility of T1 mapping in predicting clinical outcomes and for distinguishing decompensated cirrhotics from compensated cirrhotics (Bradley, 2018).

In-depth characterisation of liver tissues will be done following Couinaud segmentation of the liver. Specific to the surgical resection cohort, estimated FLR volume and cT1 will be combined to refine the LMS platform in the assessment of liver health. The significance of this in the long term resides in more accurate assessment of surgical risks, which is paramount to improve the care of HCC patients considered for surgical resection. By adopting the LMS platform to monitor patients' response to treatment longitudinally through the characterisation of their liver tissues, our study also seeks to discern features present in the LMS platform that are predictive of patients' outcomes. Additionally, this study will compare anonymized blood test results and anonymized histological reports (histological reports only for the surgical resection cohort) against features observed in the LMS platform to better discern features indicative of patients' outcomes.

This study will monitor patients closely before treatment and after their treatment with follow-up visits, and the MRI scans of these patients across these visits will be analysed using the LMS. A total of 4 MRI scans will be taken for each patient with 1st MRI scan taken within 6 weeks before treatment and the remaining MRI scans taken at the 1st, 3rd and 9th month post-initiation of treatment.

LiverMultiScan Analysis of MRI Scans in HCC

The Utility of LiverMultiScan Analysis of MRI Scans in Patients With Hepatocellular Carcinoma for Improved Prognostication and as an Aid to the Selection of Therapy

The objective is to predict the clinical outcomes of patients undergoing treatment

The objective is to refine the prediction capabilities of these software or tools. The software used in this study is the LiverMultiScan (LMS) by Perspectum which will do post-analysis of patients' MRI scans.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	NCT03717454	Prolactinoma	Surgery Drug treatment	18 Years - 65 Years	Ruijin Hospital
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)	NCT03714763	Pituitary Adeno...	Drug treatment Surgery	18 Years - 65 Years	Ruijin Hospital
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	NCT03717454	Prolactinoma	Surgery Drug treatment	18 Years - 65 Years	Ruijin Hospital
LiverMultiScan Analysis of MRI Scans in HCC	NCT04451603	Hepatocellular ...	Surgery Radiation thera... Drug treatment	21 Years - 90 Years	National Cancer Centre, Singapore

Spots Global Cancer Trial Database for drug treatment